Advertisement

Wechselwirkungen zwischen onkologischer Medikation und körperlicher Aktivität

  • Elke Jäger

Zusammenfassung

Onkologische Therapiemaßnahmen beinhalten neben operativen Eingriffen in der Regel den systemischen oder regionalen Einsatz von Zytostatika , zielgerichteten Therapeutika, „targeted therapies“ (Antikörper /Kinaseinhibitoren , Rezeptorantagonisten, Proteasominhibitoren etc.), die Bestrahlung und die antihormonelle Therapie. Während Operation und Bestrahlungstherapie akute und chronische lokale Effekte aufweisen, haben Zytostatika, Hormontherapeutika und „targeted therapies“ in der Regel systemische Auswirkungen. Abhängig von der Dauer der Intensität und der therapeutischen Beeinflussbarkeit der therapiebedingten Störungen können bewegungstherapeutische Interventionen kontraindiziert oder mit hohem supportivtherapeutischem Potential als Begleitmaßnahme eingesetzt werden. Zur adäquaten Indikationsstellung wird die interdisziplinäre Abstimmung zwischen Onkologen, Strahlentherapeuten, gegebenenfalls Psychoonkologen und Sportwissenschaftlern gefordert.

Literatur

  1. Aapro MS, Bohlius J, Cameron DA, Dal L, Donnelly J, Kearney N et al. (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European journal of cancer 47:8–32Google Scholar
  2. Ahmedzai SH (2009) Palliation of respiratory symptoms. In: Hanks GWC (ed) Oxford textbook of palliative medicine. Oxford University Press, Oxford: pp 583–616Google Scholar
  3. Alt-Epping B (2006) Tumorspezifische Therapien auch auf der Palliativstation? – Eine alte Frage neu beleuchtet. Z Palliativmed 19–24Google Scholar
  4. American Society of Clinical Oncology (1998) Cancer care during the last phase of life. Journal of clinical oncology 16:1986–1996Google Scholar
  5. Aulbert E (Hrsg) (2007) Lehrbuch der Palliativmedizin. Schattauer, StuttgartGoogle Scholar
  6. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG et al. (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. Journal of clinical oncology 15:2040–2049Google Scholar
  7. Bausewein C, Albrecht E (2009) Leitfaden Palliativmedizin – Palliative Care. Elsevier Urban & Fischer, MünchenGoogle Scholar
  8. Blank CU, Hooijkaas AI, Haanen JB, Schumacher TN (2011) Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol Immunother [Epub ahead of print]Google Scholar
  9. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578Google Scholar
  10. Browner I, Carducci M (2005) Palliative chemotherapy: historical perspective, applications, and controversies. Seminars in oncology 32:145–155Google Scholar
  11. Carbone DP, Felip E (2011) Adjuvant Therapy in Non-Small Cell Lung Cancer: Future Treatment Prospects and Paradigms. Clinical lung cancer 12:261–271Google Scholar
  12. Chan H-Y, Grossman A, Bukowski R (2010) Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Advances in therapy 27:495–511Google Scholar
  13. Chu E dVT (2008) Principles of Cancer Management. In: DeVita VT, Lawrence TS, Rosenberg SA (eds) Devita, Hellman, and Rosenberg’s Cancer. Rittenhouse Book Distributors, Inc., King of Prussia, PA: pp 289–306Google Scholar
  14. Citron M, Berry D, Cirrincione C, Hudis C, Winer E, Gradishar W et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of clinical oncology 21:1431–1439Google Scholar
  15. Clark M, Vickers K, Hathaway J, Smith M, Looker S, Petersen L et al. (2007) Physical activity in patients with advanced-stage cancer actively receiving chemotherapy. The journal of supportive oncology 5:487–493Google Scholar
  16. Coldman AJ, Goldie JH (1987) Impact of dose-intense chemotherapy on the development of permanent drug resistance. Seminars in oncology 14:29–33Google Scholar
  17. Collette L, Bosset J-F, den Dulk M, Nguyen F, Mineur L, Maingon P et al. (2007) Patients With Curative Resection of cT3-4 Rectal Cancer After Preoperative Radiotherapy or Radiochemotherapy: Does Anybody Benefit From Adjuvant Fluorouracil-Based Chemotherapy? A Trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Journal of Clinical Oncology 25:4379–4386Google Scholar
  18. Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM et al. (2007) Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 25:4396–4404Google Scholar
  19. Crevenna R, Schmidinger M, Keilani M, Nuhr M, Nur H, Zoch C et al. (2003) Aerobic exercise as additive palliative treatment for a patient with advanced hepatocellular cancer. Wiener medizinische Wochenschrift 153:237–240Google Scholar
  20. Dahlin Y, Heiwe S (2009) Patients’ experiences of physical therapy within palliative cancer care. Journal of palliative care 25:12–20Google Scholar
  21. DeVita VT, Lawrence TS, Rosenberg SA (eds) (2008) Devita, Hellman, and Rosenberg’s Cancer: Principles and practice of oncology. Rittenhouse Book Distributors, Inc., King of Prussia, PAGoogle Scholar
  22. Dimeo F, Knauf W, Geilhaupt D, Boning D (2004) Endurance exercise and the production of growth hormone and haematopoietic factors in patients with anaemia. Br J Sports Med 38:e37Google Scholar
  23. Doerr W, Herrmann T, Riesenbeck D (2005) Prävention und Therapie von Nebenwirkungen in der Radioonkologie. Uni-Med BremenGoogle Scholar
  24. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J et al. (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of clinical oncology 16:453–461Google Scholar
  25. Dorff TB, Flaig TW, Tangen CM, Hussain MHA, Swanson GP, Wood DP et al. (2011) Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study. Journal of Clinical Oncology 29:2040–2045Google Scholar
  26. Eisenberg BL, Trent JC (2011) Adjuvant and neoadjuvant imatinib therapy: Current role in the management of GIST. International Journal of Cancer 129:2533–2542Google Scholar
  27. Eklund J, Trifilio S, Mulcahy M (2005) Chemotherapy dosing in the setting of liver dysfunction. Oncology 19:1057–1063, discussion 63–64, 69Google Scholar
  28. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE et al. (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122Google Scholar
  29. Felicetti F, Manicone R, Corrias A, Manieri C, Biasin E, Bini I et al. (2011) Endocrine late effects after total body irradiation in patients who received hematopoietic cell transplantation during childhood: a retrospective study from a single institution. Journal of cancer research and clinical oncology 137:1343–1348Google Scholar
  30. Floyd J, Mirza I, Sachs B, Perry M (2006) Hepatotoxicity of chemotherapy. Seminars in oncology 33:50–67Google Scholar
  31. Frei Er, Elias A, Wheeler C, Richardson P, Hryniuk W (1998) The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clinical cancer research 4:2027–2037Google Scholar
  32. Garcia-Aguilar J, Shi Q, Thomas C, Chan E, Cataldo P, Marcet J et al. (2011) A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial. Annals of surgical oncologyGoogle Scholar
  33. Gibson TB, Ranganathan A, Grothey A (2006) Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6:29–31Google Scholar
  34. Guttman-Yassky E, Mita A, De J, Matthews L, McCarthy S, Iwata K et al. (2010) Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. European journal of cancer 46:2010–2019Google Scholar
  35. Hall EJ (2005) Radiobiology for the radiologist. JB Lippincott, PhiladelphiaGoogle Scholar
  36. Hamid O (2004) Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. J Am Pharm Assoc 44:52–58Google Scholar
  37. Hegde SR, Sun W, Lynch JP (2008) Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol 2:135–49Google Scholar
  38. Holthusen H (1936) Erfahrungen über die verträglichkeitsgrenzen von Röntgenstrahlung und deren Nutzanwendung. Strahlentherapie 57:254–269Google Scholar
  39. Hompes D, Ruers T (2011) Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. European journal of surgical oncology 37:737–746Google Scholar
  40. Horsman MR, Bohm L, Margison GP, Milas L, Rosier JF, Safrany G et al. (2006) Tumor radiosensitizers – current status of development of various approaches: report of an International Atomic Energy Agency meeting. Int J Radiat Oncol Biol Phys 64:551–561Google Scholar
  41. Horwich A (1992) Radiotherapy update. BMJ 304:1554–1557Google Scholar
  42. Hoskin P (1988) Radiotherapy and symptom management. Oxford University Press, OxfordGoogle Scholar
  43. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R (2011) Novel Therapeutic Targets in Non-small Cell Lung Cancer. J Thorac Oncol 6:1601–1612Google Scholar
  44. Johnson DH (2003) Targeted therapy in non-small cell lung cancer: myth or reality. Lung Cancer 41, Suppl 1:S3–8Google Scholar
  45. Jones L, Eves N, Haykowsky M, Freedland S, Mackey J (2009) Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. The lancet oncology 10:598–605Google Scholar
  46. Jones L, Eves N, Mackey J, Peddle C, Haykowsky M, Joy A et al. (2007) Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung cancer 55:225–232Google Scholar
  47. Kaufmann M, Jonat W, Kleeberg U, Eiermann W, Jänicke F, Hilfrich J et al. (1989) Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. Journal of clinical oncology 7:1113–1119Google Scholar
  48. Keating G (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70:1445–1476Google Scholar
  49. Kocher M, Treuer H, Muller RP (1997) Quantification of tumor reoxygenation during accelerated radiation therapy. Radiology 205:263–268Google Scholar
  50. Krause M, Ostermann G, Petersen C, Yaromina A, Hessel F, Harstrick A et al. (2005) Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 76:162–167Google Scholar
  51. Lin Z, Wu V-C, Lin J, Feng H, Chen L (2011) A longitudinal study on the radiation-induced thyroid gland changes after external beam radiotherapy of nasopharyngeal carcinoma. Thyroid 21:19–23Google Scholar
  52. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS et al. (2007) Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline. Journal of Clinical Oncology 25:1596–1605Google Scholar
  53. Lowe S, Watanabe S, Baracos V, Courneya K (2010) Physical activity interests and preferences in palliative cancer patients. Supportive care in cancer 18:1469–1475Google Scholar
  54. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730Google Scholar
  55. Mateos MV, San Miguel JF (2007) Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 20:701–715Google Scholar
  56. Medves S, Demoulin JB (2011) Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med 10 [Epub ahead of print]Google Scholar
  57. Moehler T, Goldschmidt H (2011) Therapy of relapsed and refractory multiple myeloma. Recent Results Cancer Res 183:239–271Google Scholar
  58. Molls M, Stadler P, Becker A, Feldmann HJ, Dunst J (1998) Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol 174, Suppl 4:13–16Google Scholar
  59. Negrier S, Gravis G, Perol D, Chevreau C, Delva R, Bay J-O et al. (2011) Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. The lancet oncology 12:673–680Google Scholar
  60. Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer treatment reports 61:1307–1317Google Scholar
  61. Oldervoll L, Loge J, Paltiel H, Asp M, Vidvei U, Wiken A et al. (2006) The effect of a physical exercise program in palliative care: A phase II study. Journal of pain and symptom management 31:421–430Google Scholar
  62. Papillon J, Montbarbon JF (1987) Epidermoid carcinoma of the anal canal. A series of 276 cases. Dis Colon Rectum 30:324–333Google Scholar
  63. Pietzner K, Richter R, Chekerov R, Erol E, Oskay-Ozcelik G, Lichtenegger W et al. (2011) Bevacizumab in Heavily Pre-treated and Platinum Resistant Ovarian Cancer: A Retrospective Study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group. Anticancer research 31:2679–2682Google Scholar
  64. Ponz-Sarvise M, Rodriguez J, Viudez A, Chopitea A, Calvo A, Garcia-Foncillas J et al. (2007) Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what’s new? World J Gastroenterol 13:5877–5887Google Scholar
  65. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A et al. (2011) Sunitinib and other targeted therapies for renal cell carcinoma. British journal of cancer 104:741–745Google Scholar
  66. Quintela-Fandino M, Colomer R (2011) Prediction of Response to Targeted Therapies in Lung Cancer Using Dynamic Imaging: Still Far From Clinical Implementation. J Clin Oncol 29:3716–3718Google Scholar
  67. Robertson JFR, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E et al. (2009) Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study. Journal of Clinical Oncology 27:4530–4535Google Scholar
  68. Saif MW, Longo WL, Israel G (2008) Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clin Colorectal Cancer 7:144–148Google Scholar
  69. Schmoll H-J, Höffken K, Possinger K (Hrsg) (2006) Kompendium Internistische Onkologie Standards in Diagnostik und Therapie: Teil I: Epidemiologie, Tumorbiologie, Zytostatika, Prinzipien der Tumortherapie, Supportive Maßnahmen. Teil II: Therapiekonzepte maligner Tumoren. Teil III: Indikationen und T. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  70. Schutz F, Oh W (2010) Neoadjuvant and adjuvant therapies in prostate cancer. The Urologic clinics of North America 37:97–104, Table ofContents
  71. Scripture C, Figg W (2006) Drug interactions in cancer therapy. Nature reviews 6:546–558Google Scholar
  72. Seeber S (Hrsg) (2003) Therapiekonzepte Onkologie. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  73. Smith MR (2004) Bicalutamide Monotherapy Versus Leuprolide Monotherapy for Prostate Cancer: Effects on Bone Mineral Density and Body Composition. Journal of Clinical Oncology 22:2546–2553Google Scholar
  74. Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, Humblet Y, Andre T et al. (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25:5225–5232Google Scholar
  75. Takahashi Y, Yasumoto K, Mai M (2005) Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy. Oncology reports 14:135–140Google Scholar
  76. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92:205–216Google Scholar
  77. Truong P, Gaul C, McDonald R, Petersen R, Jones S, Alexander A et al. (2011) Prospective evaluation of a 12-week walking exercise program and its effect on fatigue in prostate cancer patients undergoing radical external beam radiotherapy. American journal of clinical oncology 34:350–355Google Scholar
  78. Valachis A, Mauri D, Polyzos NP, Chlouverakis G, Mavroudis D, Georgoulias V (2011) Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis. Breast [Epub ahead of print]Google Scholar
  79. Vaupel P, Kelleher DK, Hoeckel M (2001) Tumor hypoxia as a function of hemoglobin concentration and tumor perfusion. Int J Radiat Oncol Biol Phys 76:958–959, author reply 9Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Elke Jäger
    • 1
  1. 1.II. Medizinische Klinik Hämatologie – OnkologieKrankenhaus NordwestFrankfurtDeutschland

Personalised recommendations